<DOC>
	<DOC>NCT02206646</DOC>
	<brief_summary>To monitor the safety of Metalyse速 in clinical practice in patients with acute myocardial infarction over a period of 6 years as required by Korean authorities, with the following observations: 1. Unexpected adverse drug reactions 2. Frequency and nature of adverse events (AEs) 3. Factors on the safety and efficacy profile of the Metalyse速 Injection. Efficacy of Metalyse速 was also assessed.</brief_summary>
	<brief_title>Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse速 in Korean Patients With Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>